Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
Identifieur interne : 000554 ( Main/Exploration ); précédent : 000553; suivant : 000555Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
Auteurs : Ganessan Kichenadasse [Australie] ; John O. Miners [Australie] ; Arduino A. Mangoni [Australie] ; Andrew Rowland [Australie] ; Ashley M. Hopkins [Australie] ; Michael J. Sorich [Australie]Source :
- JAMA oncology [ 2374-2445 ] ; 2020.
Abstract
Importance
High body mass index (BMI) is independently associated with overall survival benefit from immune checkpoint inhibitor therapy in patients with melanoma, yet whether BMI is associated with outcomes in patients with advanced non-small cell lung cancer treated with atezolizumab remains unknown.
Objective
To examine whether BMI is associated with survival outcomes and adverse events in patients with non-small cell lung cancer (NSCLC) treated with atezolizumab.
Design, Setting, and Participants
A pooled analysis of individual patient-level data from 4 international, multicenter clinical trials was performed. Two were single-arm phase 2 trials (BIRCH [data cutoff of May 28, 2015] and FIR [data cutoff of January 7, 2015]), and 2 were 2-arm randomized clinical trials (POPLAR [phase 2; data cutoff of May 8, 2015] and OAK [phase 3; data cutoff of July 7, 2016]). Patients with advanced NSCLC previously untreated or treated with at least 1 line of systemic therapy, with measurable disease and good organ function and without contraindications for chemotherapy or immune checkpoint inhibitor therapy, were included in these trials. Data analyses were performed from February 28, 2019, to September 30, 2019.
Interventions
The control group was treated with docetaxel once every 3 weeks until disease progression or unacceptable toxic effects occurred in POPLAR and OAK. The experimental group was treated with atezolizumab once every 3 weeks until disease progression or unacceptable toxic effects occurred in all available trials.
Main Outcomes and Measures
Association between BMI and overall survival (OS), progression-free survival (PFS), and treatment-related adverse events. Intention-to-treat analysis was conducted.
Results
Adequate data were available for 2110 patients from a total pool of 2261 across 4 trials. Of those 2110, 1434 patients (median age, 64 years [range, 57-70 years]; 890 men [62%]) received atezolizumab and 676 patients (median age, 63 years[range, 57-69 years]; 419 men [62%]) received docetaxel. There was a linear association between increasing BMI and OS in patients treated with atezolizumab. Obesity (BMI ≥30 [calculated as weight in kilograms divided by height in meters squared]) was associated with significantly improved OS in patients treated with atezolizumab, but not in those who received docetaxel after adjusting for confounding variables. The association between BMI and OS/PFS was the strongest in the high PD-L1 expression subgroup. Overall survival for patients with the highest category of PD-L1 expression (≥50% of tumor cells or ≥10% of tumor-infiltrating immune cells; n = 436) had hazard ratios of 0.36 (95% CI, 0.21-0.62) for the group with obesity and 0.69 (95% CI, 0.48-0.98) for the group with overweight. Patients with the highest category of PD-L1 expression had PFS hazard ratios of 0.68 (95% CI, 0.49-0.94) for the group with obesity and 0.72 (95% CI, 0.56-0.92) for the group with overweight. Treatment-related adverse events were not associated with BMI.
Conclusions and Relevance
High BMI appears to be independently associated with improved survival with atezolizumab in patients with NSCLC, raising the possibility that baseline BMI should be considered as a stratification factor in future immune checkpoint inhibitor therapy trials.
DOI: 10.1001/jamaoncol.2019.5241
PubMed: 31876896
PubMed Central: PMC6990855
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.</title><author><name sortKey="Kichenadasse, Ganessan" sort="Kichenadasse, Ganessan" uniqKey="Kichenadasse G" first="Ganessan" last="Kichenadasse">Ganessan Kichenadasse</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia</wicri:regionArea><wicri:noRegion>South Australia</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Flinders Centre for Innovation in Cancer, Department of Medical Oncology, Flinders Medical Centre, Flinders University, Bedford Park, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Flinders Centre for Innovation in Cancer, Department of Medical Oncology, Flinders Medical Centre, Flinders University, Bedford Park, South Australia</wicri:regionArea><wicri:noRegion>South Australia</wicri:noRegion></affiliation></author><author><name sortKey="Miners, John O" sort="Miners, John O" uniqKey="Miners J" first="John O" last="Miners">John O. Miners</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia</wicri:regionArea><wicri:noRegion>South Australia</wicri:noRegion></affiliation></author><author><name sortKey="Mangoni, Arduino A" sort="Mangoni, Arduino A" uniqKey="Mangoni A" first="Arduino A" last="Mangoni">Arduino A. Mangoni</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia</wicri:regionArea><wicri:noRegion>South Australia</wicri:noRegion></affiliation></author><author><name sortKey="Rowland, Andrew" sort="Rowland, Andrew" uniqKey="Rowland A" first="Andrew" last="Rowland">Andrew Rowland</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia</wicri:regionArea><wicri:noRegion>South Australia</wicri:noRegion></affiliation></author><author><name sortKey="Hopkins, Ashley M" sort="Hopkins, Ashley M" uniqKey="Hopkins A" first="Ashley M" last="Hopkins">Ashley M. Hopkins</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia</wicri:regionArea><wicri:noRegion>South Australia</wicri:noRegion></affiliation></author><author><name sortKey="Sorich, Michael J" sort="Sorich, Michael J" uniqKey="Sorich M" first="Michael J" last="Sorich">Michael J. Sorich</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia</wicri:regionArea><wicri:noRegion>South Australia</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:31876896</idno><idno type="pmid">31876896</idno><idno type="doi">10.1001/jamaoncol.2019.5241</idno><idno type="pmc">PMC6990855</idno><idno type="wicri:Area/Main/Corpus">000545</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000545</idno><idno type="wicri:Area/Main/Curation">000545</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000545</idno><idno type="wicri:Area/Main/Exploration">000545</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.</title><author><name sortKey="Kichenadasse, Ganessan" sort="Kichenadasse, Ganessan" uniqKey="Kichenadasse G" first="Ganessan" last="Kichenadasse">Ganessan Kichenadasse</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia</wicri:regionArea><wicri:noRegion>South Australia</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Flinders Centre for Innovation in Cancer, Department of Medical Oncology, Flinders Medical Centre, Flinders University, Bedford Park, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Flinders Centre for Innovation in Cancer, Department of Medical Oncology, Flinders Medical Centre, Flinders University, Bedford Park, South Australia</wicri:regionArea><wicri:noRegion>South Australia</wicri:noRegion></affiliation></author><author><name sortKey="Miners, John O" sort="Miners, John O" uniqKey="Miners J" first="John O" last="Miners">John O. Miners</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia</wicri:regionArea><wicri:noRegion>South Australia</wicri:noRegion></affiliation></author><author><name sortKey="Mangoni, Arduino A" sort="Mangoni, Arduino A" uniqKey="Mangoni A" first="Arduino A" last="Mangoni">Arduino A. Mangoni</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia</wicri:regionArea><wicri:noRegion>South Australia</wicri:noRegion></affiliation></author><author><name sortKey="Rowland, Andrew" sort="Rowland, Andrew" uniqKey="Rowland A" first="Andrew" last="Rowland">Andrew Rowland</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia</wicri:regionArea><wicri:noRegion>South Australia</wicri:noRegion></affiliation></author><author><name sortKey="Hopkins, Ashley M" sort="Hopkins, Ashley M" uniqKey="Hopkins A" first="Ashley M" last="Hopkins">Ashley M. Hopkins</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia</wicri:regionArea><wicri:noRegion>South Australia</wicri:noRegion></affiliation></author><author><name sortKey="Sorich, Michael J" sort="Sorich, Michael J" uniqKey="Sorich M" first="Michael J" last="Sorich">Michael J. Sorich</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia</wicri:regionArea><wicri:noRegion>South Australia</wicri:noRegion></affiliation></author></analytic><series><title level="j">JAMA oncology</title><idno type="eISSN">2374-2445</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>Importance</b></p><p>High body mass index (BMI) is independently associated with overall survival benefit from immune checkpoint inhibitor therapy in patients with melanoma, yet whether BMI is associated with outcomes in patients with advanced non-small cell lung cancer treated with atezolizumab remains unknown.</p></div><div type="abstract" xml:lang="en"><p><b>Objective</b></p><p>To examine whether BMI is associated with survival outcomes and adverse events in patients with non-small cell lung cancer (NSCLC) treated with atezolizumab.</p></div><div type="abstract" xml:lang="en"><p><b>Design, Setting, and Participants</b></p><p>A pooled analysis of individual patient-level data from 4 international, multicenter clinical trials was performed. Two were single-arm phase 2 trials (BIRCH [data cutoff of May 28, 2015] and FIR [data cutoff of January 7, 2015]), and 2 were 2-arm randomized clinical trials (POPLAR [phase 2; data cutoff of May 8, 2015] and OAK [phase 3; data cutoff of July 7, 2016]). Patients with advanced NSCLC previously untreated or treated with at least 1 line of systemic therapy, with measurable disease and good organ function and without contraindications for chemotherapy or immune checkpoint inhibitor therapy, were included in these trials. Data analyses were performed from February 28, 2019, to September 30, 2019.</p></div><div type="abstract" xml:lang="en"><p><b>Interventions</b></p><p>The control group was treated with docetaxel once every 3 weeks until disease progression or unacceptable toxic effects occurred in POPLAR and OAK. The experimental group was treated with atezolizumab once every 3 weeks until disease progression or unacceptable toxic effects occurred in all available trials.</p></div><div type="abstract" xml:lang="en"><p><b>Main Outcomes and Measures</b></p><p>Association between BMI and overall survival (OS), progression-free survival (PFS), and treatment-related adverse events. Intention-to-treat analysis was conducted.</p></div><div type="abstract" xml:lang="en"><p><b>Results</b></p><p>Adequate data were available for 2110 patients from a total pool of 2261 across 4 trials. Of those 2110, 1434 patients (median age, 64 years [range, 57-70 years]; 890 men [62%]) received atezolizumab and 676 patients (median age, 63 years[range, 57-69 years]; 419 men [62%]) received docetaxel. There was a linear association between increasing BMI and OS in patients treated with atezolizumab. Obesity (BMI ≥30 [calculated as weight in kilograms divided by height in meters squared]) was associated with significantly improved OS in patients treated with atezolizumab, but not in those who received docetaxel after adjusting for confounding variables. The association between BMI and OS/PFS was the strongest in the high PD-L1 expression subgroup. Overall survival for patients with the highest category of PD-L1 expression (≥50% of tumor cells or ≥10% of tumor-infiltrating immune cells; n = 436) had hazard ratios of 0.36 (95% CI, 0.21-0.62) for the group with obesity and 0.69 (95% CI, 0.48-0.98) for the group with overweight. Patients with the highest category of PD-L1 expression had PFS hazard ratios of 0.68 (95% CI, 0.49-0.94) for the group with obesity and 0.72 (95% CI, 0.56-0.92) for the group with overweight. Treatment-related adverse events were not associated with BMI.</p></div><div type="abstract" xml:lang="en"><p><b>Conclusions and Relevance</b></p><p>High BMI appears to be independently associated with improved survival with atezolizumab in patients with NSCLC, raising the possibility that baseline BMI should be considered as a stratification factor in future immune checkpoint inhibitor therapy trials.</p></div></front></TEI><pubmed><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">31876896</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2374-2445</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA oncology</Title><ISOAbbreviation>JAMA Oncol</ISOAbbreviation></Journal><ArticleTitle>Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.</ArticleTitle><Pagination><MedlinePgn>512-518</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaoncol.2019.5241</ELocationID><Abstract><AbstractText Label="Importance" NlmCategory="UNASSIGNED">High body mass index (BMI) is independently associated with overall survival benefit from immune checkpoint inhibitor therapy in patients with melanoma, yet whether BMI is associated with outcomes in patients with advanced non-small cell lung cancer treated with atezolizumab remains unknown.</AbstractText><AbstractText Label="Objective" NlmCategory="UNASSIGNED">To examine whether BMI is associated with survival outcomes and adverse events in patients with non-small cell lung cancer (NSCLC) treated with atezolizumab.</AbstractText><AbstractText Label="Design, Setting, and Participants" NlmCategory="UNASSIGNED">A pooled analysis of individual patient-level data from 4 international, multicenter clinical trials was performed. Two were single-arm phase 2 trials (BIRCH [data cutoff of May 28, 2015] and FIR [data cutoff of January 7, 2015]), and 2 were 2-arm randomized clinical trials (POPLAR [phase 2; data cutoff of May 8, 2015] and OAK [phase 3; data cutoff of July 7, 2016]). Patients with advanced NSCLC previously untreated or treated with at least 1 line of systemic therapy, with measurable disease and good organ function and without contraindications for chemotherapy or immune checkpoint inhibitor therapy, were included in these trials. Data analyses were performed from February 28, 2019, to September 30, 2019.</AbstractText><AbstractText Label="Interventions" NlmCategory="UNASSIGNED">The control group was treated with docetaxel once every 3 weeks until disease progression or unacceptable toxic effects occurred in POPLAR and OAK. The experimental group was treated with atezolizumab once every 3 weeks until disease progression or unacceptable toxic effects occurred in all available trials.</AbstractText><AbstractText Label="Main Outcomes and Measures" NlmCategory="UNASSIGNED">Association between BMI and overall survival (OS), progression-free survival (PFS), and treatment-related adverse events. Intention-to-treat analysis was conducted.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">Adequate data were available for 2110 patients from a total pool of 2261 across 4 trials. Of those 2110, 1434 patients (median age, 64 years [range, 57-70 years]; 890 men [62%]) received atezolizumab and 676 patients (median age, 63 years[range, 57-69 years]; 419 men [62%]) received docetaxel. There was a linear association between increasing BMI and OS in patients treated with atezolizumab. Obesity (BMI ≥30 [calculated as weight in kilograms divided by height in meters squared]) was associated with significantly improved OS in patients treated with atezolizumab, but not in those who received docetaxel after adjusting for confounding variables. The association between BMI and OS/PFS was the strongest in the high PD-L1 expression subgroup. Overall survival for patients with the highest category of PD-L1 expression (≥50% of tumor cells or ≥10% of tumor-infiltrating immune cells; n = 436) had hazard ratios of 0.36 (95% CI, 0.21-0.62) for the group with obesity and 0.69 (95% CI, 0.48-0.98) for the group with overweight. Patients with the highest category of PD-L1 expression had PFS hazard ratios of 0.68 (95% CI, 0.49-0.94) for the group with obesity and 0.72 (95% CI, 0.56-0.92) for the group with overweight. Treatment-related adverse events were not associated with BMI.</AbstractText><AbstractText Label="Conclusions and Relevance" NlmCategory="UNASSIGNED">High BMI appears to be independently associated with improved survival with atezolizumab in patients with NSCLC, raising the possibility that baseline BMI should be considered as a stratification factor in future immune checkpoint inhibitor therapy trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kichenadasse</LastName><ForeName>Ganessan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Flinders Centre for Innovation in Cancer, Department of Medical Oncology, Flinders Medical Centre, Flinders University, Bedford Park, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miners</LastName><ForeName>John O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mangoni</LastName><ForeName>Arduino A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowland</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hopkins</LastName><ForeName>Ashley M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorich</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders University, Bedford Park, South Australia, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Oncol</MedlineTA><NlmUniqueID>101652861</NlmUniqueID><ISSNLinking>2374-2437</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31876896</ArticleId><ArticleId IdType="pii">2757521</ArticleId><ArticleId IdType="doi">10.1001/jamaoncol.2019.5241</ArticleId><ArticleId IdType="pmc">PMC6990855</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li></country></list><tree><country name="Australie"><noRegion><name sortKey="Kichenadasse, Ganessan" sort="Kichenadasse, Ganessan" uniqKey="Kichenadasse G" first="Ganessan" last="Kichenadasse">Ganessan Kichenadasse</name></noRegion><name sortKey="Hopkins, Ashley M" sort="Hopkins, Ashley M" uniqKey="Hopkins A" first="Ashley M" last="Hopkins">Ashley M. Hopkins</name><name sortKey="Kichenadasse, Ganessan" sort="Kichenadasse, Ganessan" uniqKey="Kichenadasse G" first="Ganessan" last="Kichenadasse">Ganessan Kichenadasse</name><name sortKey="Mangoni, Arduino A" sort="Mangoni, Arduino A" uniqKey="Mangoni A" first="Arduino A" last="Mangoni">Arduino A. Mangoni</name><name sortKey="Miners, John O" sort="Miners, John O" uniqKey="Miners J" first="John O" last="Miners">John O. Miners</name><name sortKey="Rowland, Andrew" sort="Rowland, Andrew" uniqKey="Rowland A" first="Andrew" last="Rowland">Andrew Rowland</name><name sortKey="Sorich, Michael J" sort="Sorich, Michael J" uniqKey="Sorich M" first="Michael J" last="Sorich">Michael J. Sorich</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000554 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000554 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PoplarV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:31876896
|texte= Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:31876896" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PoplarV1
| This area was generated with Dilib version V0.6.37. |  |